CD20 + CD22 + CD10 chimeric antigen receptor T-cell therapy

CD20 + CD22 + CD10 chimeric antigen receptor T-cell therapy is an experimental trivalent CAR-T cell therapy currently in early-phase clinical development for the treatment of refractory or relapsed B-cell malignancies. Unlike conventional monospecific CAR-T therapies that target a single antigen (such as CD19), this construct is engineered to simultaneously recognize three distinct B-cell surface markers: CD20, CD22, and CD10 (also known as neprilysin or CALLA). This multi-targeting approach is specifically designed to mitigate the risk of antigen escape, a phenomenon where cancer cells downregulate a single target to evade immune detection, leading to treatment resistance and relapse. CD10 is a particularly relevant target for B-cell acute lymphoblastic leukemia (B-ALL), while CD20 and CD22 provide broad coverage across various stages of B-cell maturation. The therapy involves ex vivo genetic modification of autologous T cells to express chimeric antigen receptors, which, upon re-infusion, direct the immune system to identify and eliminate malignant B cells expressing any of the three target antigens.

Other names

CD10/CD20/CD22 trivalent CAR-Ttrivalent CD10/CD20/CD22 CAR-T cells